Financial Performance - Total revenues for Q2 2024 were $1,306,000, a slight increase of 0.7% compared to $1,297,000 in Q2 2023[2] - The company reported a net income of $1,061,000 for Q2 2024, compared to a net income of $818,000 in Q2 2023, representing a 29.7% increase[2] - Basic and diluted net income per share attributable to common stockholders was $0.78 for Q2 2024, compared to $0.61 in Q2 2023, reflecting improved profitability[2] - Net loss for the six months ended June 30, 2024, was $1,362 million, a significant improvement from a loss of $8,566 million in the same period of 2023[4] Operating Expenses and Management - Operating expenses for Q2 2024 were $674,000, significantly lower than $2,751,000 in Q2 2023, indicating improved cost management[2] - The company recorded stock-based compensation of $240 million, down from $411 million in the same period last year[4] Cash and Liquidity - Cash and cash equivalents decreased to $5,504,000 as of June 30, 2024, down from $6,518,000 at the end of 2023[1] - Current liabilities decreased to $2,698,000 as of June 30, 2024, down from $3,590,000 at the end of 2023, showing improved liquidity[1] - Cash flows from investing activities provided $4,647 million, compared to a cash outflow of $4,401 million in the prior year[4] - The net cash used in operating activities was $5,666 million, a decrease from $8,264 million in the prior year[4] Assets and Equity - Total assets decreased to $17,369,000 as of June 30, 2024, compared to $19,705,000 at the end of 2023, reflecting a reduction in current assets[1] - The company’s total stockholders' equity decreased to $11,566,000 as of June 30, 2024, down from $12,703,000 at the end of 2023[1] - The accumulated deficit increased to $(273,202,000) as of June 30, 2024, compared to $(271,840,000) at the end of 2023[1] Gains and Losses - The company reported a gain on the sale of intangible assets of $(4,000,000) in Q2 2024, which impacted overall income[2] - The company reported a gain of $4,000 million from the sale of RS durum wheat trait, with no comparable figure in the previous year[4] - The company had a valuation loss on March 2023 PIPE of $85 million, compared to a significant loss of $6,076 million in the previous year[4] Other Financial Activities - Proceeds from the sale of investments amounted to $2,501 million, with no such proceeds reported in the previous year[4] - Proceeds from the issuance of common stock and preferred investment options from March 2023 PIPE were $5,997 million, with no such proceeds in the current period[4] - The company experienced a decrease in accounts payable and accrued expenses by $612 million, compared to a decrease of $149 million in the same period last year[4]

Arcadia Biosciences (RKDA) announced that it inked a deal with Above Food Corp. to sell its GoodWheat brand for $4 million. This move will allow Arcadia to scale its wheat IP by leveraging Above Food's vertically integrated farm-to-fork supply network. GoodWheat, which was launched in 2018, uses Arcadia's unique, patented and healthier wheat grain, which is naturally higher in fiber and protein. In June 2022, the company launched five variations of GoodWheat pasta, followed by six varieties of pancake mixes ...

The company reported an adjusted loss of $1.78 per share in the first quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of $2.52. This compares to a loss of $3.86 in the year-ago quarter. The company had recorded a valuation loss of $6 million related to March 2023 financing transaction in the first quarter of 2023. Including this, RKDA had reported a loss per share of $10.86 in the first quarter of 2023. Net sales were $1.26 million in the quarter under review, which marked a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Arcadia Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-0571538 (State or other jurisdiction of incorporation or organization) 5950 Sherry Lane, Suite 215 Dallas, TX 75225 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC ...

Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants T.J. Schaefer - Chief Financial Officer Stan Jacot - President & Chief Executive Officer Conference Call Participants Ben Klieve - Lake Street Operator Thank you for standing by. My name is Parilla, and I will be your conference operator today. At this time, I would like to welcome everyone to the Arcadia Biosciences Q1 2024 Financial Results and Business Highlights Conference Call. All line ...

Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share data and per share data) | | | | Three Months Ended March 31, | | | --- | --- | --- | --- | --- | | | | 2024 | | 2023 | | Revenues: | | | | | | Product | $ | 1,255 | $ | 1,232 | | Total revenues | | 1,255 | | 1,232 | | Operating expenses (income): | | | | | | Cost of revenues | | 820 | | 688 | | Research and development | | 272 | | 359 | | Loss (Gain) on sale of property and equipment | | 2 | | (19 ) | ...

Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q4 2023 Earnings Conference Call March 28, 2024 4:30 PM ET Company Participants T.J. Schaefer – Chief Financial Officer Stan Jacot – President and Chief Executive Officer Conference Call Participants Ben Klieve – Lake Street Capital Markets Dipesh Patel – H.C. Wainwright Operator Good afternoon and welcome to the Arcadia Biosciences Fourth Quarter and Full Year 2023 Financial Results and Business Highlights Conference Call. At this time all participants are in a liste ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37383 Arcadia Biosciences, Inc. (Exact name of Registrant as specified in its Charter) Delaware 81-0571538 (State or ot ...

1 Arcadia Biosciences, Inc. Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except share data and per share data) | | | | Year Ended December 31, | | | --- | --- | --- | --- | --- | | | | 2023 | | 2022 | | Revenues: | | | | | | Product | $ | 5,313 | $ | 6,422 | | License | | 17 | | 879 | | Royalty | | — | | — | | Total revenues | | 5,330 | | 7,301 | | Operating expenses (income): | | | | | | Cost of revenues | | 3,300 | | 6,101 | | Research and development | | 1,387 | ...

Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants T.J. Schaefer - Chief Financial Officer Stan Jacot - President and Chief Executive Officer Conference Call Participants Dipesh Patel - H.C. Wainwright & Co Ben Klieve - Lake Street Capital Markets Operator Good afternoon and welcome to Arcadia Biosciences Third Quarter 2023 Financial Results and Business Highlights Conference Call. [Operator Instructions] Please be advised that today’s c ...